[DISCLOSURE] ST Pharm (237690) said on Sept. 19 that it has signed a contract worth 151.9 billion won (US$135.5 million) with Gilead Sciences Ireland UC to supply anti-viral active pharmaceutical ingredient.
The deal amounts to 110.06 percent of its revenue in 2015 and expires Nov. 30.
